A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
Jazz Pharmaceuticals
Jazz Pharmaceuticals
Inspirna, Inc.
Boehringer Ingelheim
Sumitomo Pharma America, Inc.
Isofol Medical AB
Epidemiological and Clinical Research Information Network
AIO-Studien-gGmbH
National Cancer Institute (NCI)